Effect of Science Research Wellness Ndo1 on Glycaemia in Adults With Pre-diabetes

NCT06897462 | Completed

• 1 other identifier: WEL202401
• Study Type: interventional
• Target: 14
• Locations: 1 country
• Sites: 1

Brief Summary

The objective of this study is to test the effect of 12 weeks of supplementation SRW Ndo1 on metabolic health and general health in adults with prediabetes. The primary question it aims to answer are:

• How does SRW Ndo1 affect the Haemoglobin A1C (HbA1C) test outcome for adult individuals?
• How does SRW Ndo1 affect the body measures and blood pressures of adult individuals? Investigators will compare the supplement to a placebo (a look-alike substance that contains no supplement) to see if SRW Ndo1 works to support normal blood sugar metabolism. Participants will:
• Take supplement SRW Ndo1, two capsules a day for 12 weeks.
• Be asked to refrain from changing their diet and lifestyle drastically during the study and to refrain from starting new health supplements during the study.
• Visit the clinic at the start and the end of intervention for a blood test (8 hour fasting required prior to test)
• Keep a diary of their symptoms or adverse events during intervention.

Conditions

Prediabetes

Keywords

Diabetes; prediabetes

Outcome Measures

Primary Outcomes (1)

• Serum Hemoglobin A1C (HbA1c) concentration

  Measured in mmol/mol. Normal range: \<5.7

  From enrollment to the end of treatment at 12 weeks

Secondary Outcomes (13)

• Fasting plasma glucose concentration

  From enrollment to the end of treatment at 12 weeks

• Weight

  From enrollment to the end of treatment at 12 weeks

• Body Mass Index (BMI)

  From enrollment to the end of treatment at 12 weeks

• Waist circumference

  From enrollment to the end of treatment at 12 weeks

• Blood lipids

  From enrollment to the end of treatment at 12 weeks

Study Arms (1)

SRW Ndo1

EXPERIMENTAL

Active arm The investigational product (IP) is a health supplement that contains 80 mg of dahlia4® (Dahlia pinnata extract), 80 mg of Eriomin® (Citrus limon extract), and 100 mg of Mulberry leaf extract (with 5% 1-deoxynojirimycin) per capsule. Excipients include Microcrystalline cellulose, Magnesium stearate, and Colloidal silicon dioxide. Participants will take two capsules of Ndo1 per day, before dinner, with water, for 12 weeks.

Dietary Supplement: SRW Ndo1

Interventions

SRW Ndo1 DIETARY_SUPPLEMENT

The investigational product (IP) is a health supplement for glycaemic control. Each capsule contains 80 mg of dahlia4® (Dahlia pinnata extract), 80 mg of Eriomin® (Citrus limon extract), and 100 mg of Mulberry leaf extract (with 5% 1-deoxynojirimycin).

SRW Ndo1

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age 18 years and over.
• Prediabetes, defined as fasting plasma glucose of 6.1-6.9 mmol/L and/or HbA1c of 5.7-6.4% and/or 2 h plasma glucose of 7.8-11.0 mmol/L after ingestion of 75 g of oral glucose load. Blood tests conducted within 3 months before randomisation will be accepted.
• Able to read and write English.
• Has access to internet.
• Provided informed consent to participate in the study.

You may not qualify if:

• Has a medical condition known to affect the glycaemia.
• Regular intake of a health supplement with effects on glycaemia.
• Currently participating in another trial/study of a supplement or drug.
• Has any known food or allergy or intolerances to the ingredients of the intervention.
• Pregnant, trying to conceive or breastfeeding.
• Has any current substance abuse (including tobacco, alcohol and recreational drugs) or currently in substance withdrawal.
• Moderate to severe medical conditions (defined as a significant impact on social areas of functioning).
• Any medical conditions that was not stable over the last 3 months.
• Taking any prescription medication known to affect glycaemia or had a change in their medication within the last 3 months.
• Currently taking celiprolol, metformin, or any angiotensin-converting enzyme inhibitor medications.
• Major medical or surgical event requiring hospitalization within the last 3 months.
• Any other medical reason that may make participation in this study pose a risk to the participant, including potential herb-drug interactions, at the discretion of the study medical supervisor.

Sponsors & Collaborators

• Wellizen Australia: lead

Study Sites (1)

Baohua

Guangzhou, Guandong, China

Location

MeSH Terms

Conditions

Prediabetic State; Diabetes Mellitus

Condition Hierarchy (Ancestors)

Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Endocrine System Diseases

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 9, 2025
• First Posted: March 27, 2025
• Study Start: April 1, 2025
• Primary Completion: July 1, 2025
• Study Completion: July 8, 2025
• Last Updated: July 24, 2025

Record last verified: 2025-07

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)